BRA
CLVS

Bender Robert & Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Bender Robert & Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$60K – 56
2022
Q3 		$60K Hold
50,000
– – 0.02% 50
2022
Q2 		$90K Buy
+50,000
New +$73.8K 0.03% 51
2021
Q2 		– Sell
-50,000
Closed -$351K – 57
2021
Q1 		$351K Buy
+50,000
New +$335K 0.11% 47

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Bender Robert & Associates's CLVS Position: Q4 2022 in Review

Bender Robert & Associates sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 50,000 shares — an estimated $60K sold.

Bender Robert & Associates first reported a position in CLVS in Q1 2021 and held it in 3 quarters. The position peaked at $351K in Q1 2021. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Bender Robert & Associates reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Bender Robert & Associates sold 50,000 Clovis Oncology, Inc. shares in Q4 2022, an estimated $60K.
  • Bender Robert & Associates first reported a position in Clovis Oncology, Inc. in Q1 2021 and held it in 3 quarters.
  • Bender Robert & Associates's Clovis Oncology, Inc. position peaked at $351K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Bender Robert & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.